CD36 expression is induced in patients with HER2-positive breast cancer treated with anti-HER2 therapies and is associated with poor prognosis, whereas CD36 knockdown by siRNA promotes cell apoptosis and suppresses tumor growth [42]. Here, CD36 is linked to neoplasm.